Indian stock markets ended a three-day losing streak with a gain of 0.8 percent on Monday. This rise followed positive movements in Asian m...

Silver and gold ETFs saw gains of up to 3% on Monday, despite a lower opening for bullion prices on MCX. Rising crude oil prices fueled inf...

Sun Pharmaceutical is making its biggest move yet with a $13 billion offer for Organon & Co. This ambitious bid aims to transform the India...

Indian equity benchmarks declined for a second straight session, pressured by a spike in crude oil prices, a weakening rupee and rising geo...

Pharma stocks fell Thursday after reports of US President Donald Trump mulling 100% tariffs on imported branded and patented medicine maker...

Indian drug maker Sun Pharma faces significant exposure to potential US tariffs on medicines. Global brokerage Jefferies warns that while g...

Pharma stocks fell after reports that the Trump administration may impose tariffs—potentially up to 100%—on drugmakers not ensuring low pri...

The Trump administration is aggressively pursuing deals across 20-30 critical industries, offering incentives like equity stakes and regula...

US stock futures moved up and down as traders watched new tariff news and waited for an inflation report. Some big companies like Intel, El...

The Nifty Pharma Index ended 0.2% higher Monday after tumbling almost 2.4% earlier in the day in response to Trump's remarks. The Sensex an...

Indian pharmaceutical stocks experienced a significant decline. This followed US President Donald Trump's executive order. The order aims t...

Shares of Indian pharma companies, including Aurobindo Pharma, Laurus Labs, IPCA Labs, and Lupin, fell up to 8% after U.S. President Donald...

Dr. Reddy’s Laboratories fell 5.8% to Rs 1,128.90, while Zydus Lifesciences dropped 4.8%. Sun Pharma, India's largest drugmaker, declined b...

The pharma funds have returned 0.37 per cent in one week, 2.33 per cent in one month, -0.98 per cent in three months and -3.48 per cent in ...

The pharma fund category lost 5%, while the technology segment is down 3% in the past year, according to Morningstar. During the same perio...

Pharma funds have lost 5 per cent, while the IT segment is down 3% in the past year.

If they have spare cash, mutual fund investors can consider daily STP to benefit from the current market.